Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03157128
Other study ID # 17477
Secondary ID J2G-OX-JZJALOXO-
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 2, 2017
Est. completion date February 28, 2026

Study information

Verified date March 2024
Source Eli Lilly and Company
Contact There may be multiple sites in this clinical trial. 1-877-CTLILL
Phone 1-317-615-4559
Email ClinicalTrials.gov@lilly.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.


Description:

This is an open-label, multi-center Phase 1/2 study in participants with advanced solid tumors, including RET fusion-positive solid tumors, MTC, and other tumors with RET activation. The trial will be conducted in 2 parts: Phase 1 (dose escalation - completed) and phase 2 (dose expansion). Participants with advanced cancer are eligible if they have progressed on or are intolerant to available standard therapies, or no standard or available curative therapy exists, or in the opinion of the Investigator, they would be unlikely to tolerate or derive significant clinical benefit from appropriate standard of care therapy, or they declined standard therapy. A dose of 160 milligrams (mg) twice a day (BID) has been selected as the recommended phase 2 dose (RP2D). Approximately 875 participants with advanced solid tumors harboring a RET gene alteration in tumor and/or blood will be enrolled to one of seven phase 2 cohorts: - Cohort 1: Advanced RET fusion positive solid tumor other than NSCLC or thyroid cancer for participants who progressed on or intolerant to first line therapy (open) - Cohort 2: Advanced RET fusion positive solid tumor other than NSCLC or thyroid cancer for treatment naïve participants (open) - Cohort 3: Advanced RET-mutant MTC participants who progressed on or intolerant to first line therapy (closed) - Cohort 4: Advanced RET-mutant MTC participants who are treatment naïve (closed) - Cohort 5: Advanced RET-altered solid tumor for participants other than NSCLC or thyroid cancer and RET-mutant MEN2 spectrum tumors (e.g. pheochromocytoma) otherwise ineligible for cohorts 1-4. See details in inclusion/exclusion criteria (open) - Cohort 6: Participants otherwise eligible for Cohorts 1-5 who discontinued another RET inhibitor due to intolerance may be eligible with prior Sponsor approval (closed) - Cohort 7: RET fusion positive early-stage non-small cell lung cancer (NSCLC) participants who are candidates for definitive surgery. Participants will receive selpercatinib in a neoadjuvant and adjuvant setting. Participants will be followed for disease recurrence for up to 5 years from the date of surgery (closed)


Recruitment information / eligibility

Status Recruiting
Enrollment 875
Est. completion date February 28, 2026
Est. primary completion date February 28, 2025
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Key Inclusion Criteria: For Phase 1: - Participants with a locally advanced or metastatic solid tumor that: - Has progressed on or is intolerant to standard therapy, or - For which no standard therapy exists, or in the opinion of the Investigator, are not candidates for or would be unlikely to tolerate or derive significant clinical benefit from standard therapy, or - Decline standard therapy - Prior multikinase inhibitors (MKIs) with anti-RET activity are allowed - A RET gene alteration is not required initially. Once adequate PK exposure is achieved, evidence of RET gene alteration in tumor and/or blood is required as identified through molecular assays, as performed for clinical evaluation - Measurable or non-measurable disease as determined by RECIST 1.1 or RANO as appropriate to tumor type - Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2 or Lansky Performance Score (LPS) greater than or equal to (=) 40 percent (%) (age less than [<] 16 years) with no sudden deterioration 2 weeks prior to the first dose of study treatment - Adequate hematologic, hepatic and renal function - Life expectancy of at least 3 months For Phase 2: As for phase 1 with the following modifications: - For Cohort 1: Participants must have received prior standard therapy appropriate for their tumor type and stage of disease, or in the opinion of the Investigator, would be unlikely to tolerate or derive clinical benefit from appropriate standard of care therapy - Cohorts 1 and 2: - Enrollment will be restricted to participants with evidence of a RET gene alteration in tumor - At least one measurable lesion as defined by RECIST 1.1 or RANO, as appropriate to tumor type and not previously irradiated - Cohorts 3 and 4: Enrollment closed - Cohort 5: - Cohorts 1-4 without measurable disease - MCT not meeting the requirements for Cohorts 3 or 4 - MTC syndrome spectrum cancers (e.g., MTC, pheochromocytoma), cancers with neuroendocrine features/differentiation, or poorly differentiated thyroid cancers with other RET alteration/activation may be allowed with prior Sponsor approval - cfDNA positive for a RET gene alteration not known to be present in a tumor sample - Cohort 6: Participants who otherwise are eligible for Cohorts 1, 2 or 5 who discontinued another RET inhibitor may be eligible with prior Sponsor approval - Cohort 7: Participants with a histologically confirmed stage IB-IIIA NSCLC and a RET fusion; determined to be medically operable and tumor deemed resectable by a thoracic surgical oncologist, without prior systemic treatment for NSCLC Key Exclusion Criteria (Phase 1 and Phase 2): - Phase 2 Cohorts 1 and 2: an additional known oncogenic driver - Cohorts 3 and 4: Enrollment closed - Cohorts 1, 2 and 5: prior treatment with a selective RET inhibitor Notes: Participants otherwise eligible for Cohorts 1, 2, and 5 who discontinued another selective RET inhibitor may be eligible for Phase 2 Cohort 6 with prior Sponsor approval - Investigational agent or anticancer therapy (including chemotherapy, biologic therapy, immunotherapy, anticancer Chinese medicine or other anticancer herbal remedy) within 5 half-lives or 2 weeks (whichever is shorter) prior to planned start of LOXO-292 (selpercatinib). In addition, no concurrent investigational anti-cancer therapy is permitted Note: Potential exception for this exclusion criterion will require a valid scientific justification and approval from the Sponsor - Major surgery (excluding placement of vascular access) within 2 weeks prior to planned start of LOXO-292 (selpercatinib) - Radiotherapy with a limited field of radiation for palliation within 1 week of planned start of LOXO-292 (selpercatinib), with the exception of participants receiving radiation to more than 30% of the bone marrow or with a wide field of radiation, which must be completed at least 4 weeks prior to the first dose of study treatment - Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy - Symptomatic primary CNS tumor, metastases, leptomeningeal carcinomatosis, or untreated spinal cord compression. Participants are eligible if neurological symptoms and CNS imaging are stable and steroid dose is stable for 14 days prior to the first dose of LOXO-292 (selpercatinib) and no CNS surgery or radiation has been performed for 28 days, 14 days if stereotactic radiosurgery (SRS) - Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of LOXO-292 (selpercatinib) or prolongation of the QT interval corrected (QTcF) greater than (>) 470 milliseconds (msec) - Participants with implanted pacemakers may enter the study without meeting QTc criteria due to nonevaluable measurement if it is possible to monitor for QT changes. - Participants with bundle branch block may be considered for study entry if QTc is appropriate by a formula other than Fridericia's and if it is possible to monitor for QT changes. - Required treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers and certain prohibited concomitant medications - Phase 2 Cohort 7 (neoadjuvant treatment): Participant must not have received prior systemic therapy for NSCLC.

Study Design


Intervention

Drug:
LOXO-292
Oral LOXO-292

Locations

Country Name City State
Australia Peter MacCallum Cancer Centre Melbourne Victoria
Australia Royal North Shore Hospital St. Leonards New South Wales
Canada BC Cancer Vancouver Vancouver British Columbia
Denmark Rigshospitalet Copenhagen København Ø
France Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest Bordeaux
France Centre Leon Berard Lyon Cedex 08
France APHM Hôpital de la Timone Marseille
France Institut du Cancer de Montpellier - Val d'aurelle Montpellier Cedex 5
France Hôpital Européen Georges Pompidou Paris Cedex 15
France Gustave Roussy Villejuif Cedex
Germany Universitätsklinikum Köln Köln Nordrhein-Westfalen
Germany Universitätsklinikum Würzburg A. ö. R. Würzburg Bayern
Hong Kong Prince of Wales Hospital Hong Kong Shatin, New Territories
Israel Soroka Medical Center - Pediatric Outpatient Clinic Beer-Sheva
Israel Hadassah Medical Center Jerusalem
Israel Shaare Zedek Medical Center Jerusalem Yerushalayim
Israel Sheba Medical Center Tel Hashomer Ramat Gan
Italy Istituto Nazionale dei Tumori Milano Lombardie
Japan Hyogo Cancer Center Akashi Hyogo
Japan National Cancer Center Hospital Chuo-ku Tokyo
Japan National Hospital Organization Kyushu Cancer Center Fukuoka
Japan Kanazawa University Hospital Kanazawa Ishikawa
Japan National Cancer Center Hospital East Kashiwa Chiba
Japan Japanese Foundation for Cancer Research Koto Tokyo
Japan Tominaga Hospital Nagaizumi-cho,Sunto-gun Shizuoka
Japan Nagoya University Hospital Nagoya Aichi
Japan Okayama University Hospital Okayama
Japan Osaka City General Hospital Osaka
Japan Kindai University Hospital Osaka Sayama-shi Osaka
Japan Hokkaido University Hospital Sapporo Hokkaido
Japan Tottori University Hospital Yonago Tottori
Korea, Republic of National Cancer Center Goyang-si Gyeonggi-do
Korea, Republic of Seoul National University Bundang Hospital Seongnam Kyonggi-do
Korea, Republic of Asan Medical Center Seoul Seoul-teukbyeolsi [Seoul]
Korea, Republic of Samsung Medical Center Seoul Seoul-teukbyeolsi [Seoul]
Korea, Republic of Severance Hospital, Yonsei University Health System Seoul
Singapore National Cancer Centre Singapore Singapore
Spain Hospital Universitari Vall d'Hebron Barcelona Barcelona [Barcelona]
Spain Hospital Madrid Norte Sanchinarro Madrid
Spain Hospital Universitario Fundación Jiménez Díaz Madrid
Switzerland Kantonsspital Luzern Luzern 16 Luzern
Taiwan Taichung Veterans General Hospital Taichung
Taiwan National Taiwan University Hospital Taipei
United Kingdom Royal Marsden Hospital Sutton Surrey
United States University of Michigan Ann Arbor Michigan
United States Emory University Atlanta Georgia
United States University of Maryland Medical Center Baltimore Maryland
United States Dana-Farber Cancer Institute Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts
United States Roswell Park Cancer Institute Buffalo New York
United States University of North Carolina Chapel Hill North Carolina
United States University of Chicago Medicine-Comprehensive Cancer Center Chicago Illinois
United States Cleveland Clinic Foundation Cleveland Ohio
United States Ohio State University Hospital Columbus Ohio
United States University of Texas Southwestern Medical Center at Dallas Dallas Texas
United States Sarah Cannon Research Institute at HealthOne Denver Colorado
United States City of Hope National Medical Center Duarte California
United States USO-Virginia Cancer Specialists, PC Fairfax Virginia
United States START Midwest Grand Rapids Michigan
United States University of Texas MD Anderson Cancer Center Houston Texas
United States Mayo Clinic in Florida Jacksonville Florida
United States University of California - San Diego La Jolla California
United States Comprehensive Cancer Centers of Nevada Las Vegas Nevada
United States UCLA Medical Center Los Angeles California
United States University of Wisconsin-Madison Hospital and Health Clinic Madison Wisconsin
United States Vanderbilt University Medical Center Nashville Tennessee
United States Yale Cancer Center New Haven Connecticut
United States Ochsner Clinic Foundation New Orleans Louisiana
United States Memorial Sloan Kettering Cancer Center New York New York
United States NYU Langone New York New York
United States Hoag Memorial Hospital Presbyterian Newport Beach California
United States Irvine Medical Center Orange California
United States Memorial Hospital Pembroke Pembroke Florida
United States Thomas Jefferson University Philadelphia Pennsylvania
United States University of Pennsylvania Hospital Philadelphia Pennsylvania
United States Oregon Health and Science University Portland Oregon
United States Mayo Clinic Rochester Minnesota
United States Washington University Medical School Saint Louis Missouri
United States Huntsman Cancer Institute Salt Lake City Utah
United States UCSF Medical Center at Mission Bay San Francisco California
United States Kaiser Permanente Santa Clara California
United States Mayo Clinic of Scottsdale Scottsdale Arizona
United States Kaiser Permanente Medical Center Vallejo California
United States Johns Hopkins University Washington District of Columbia

Sponsors (2)

Lead Sponsor Collaborator
Loxo Oncology, Inc. Eli Lilly and Company

Countries where clinical trial is conducted

United States,  Australia,  Canada,  Denmark,  France,  Germany,  Hong Kong,  Israel,  Italy,  Japan,  Korea, Republic of,  Singapore,  Spain,  Switzerland,  Taiwan,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase 1: MTD Incidence rate and category of dose limiting toxicities (DLTs) during the first 28-day cycle of LOXO-292 (selpercatinib) treatment The first 28 days of treatment (Cycle 1)
Primary Phase 1: RP2D Phase 1: RP2D The first 28 days of treatment (Cycle 1) and every cycle (28 days) for approximately 12 months (or earlier if the participant discontinues from the study)
Primary Phase 2: Objective Response Rate As assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or Response Assessment in Neuro-Oncology (RANO), as appropriate to tumor type, as assessed by independent review committee (IRC) Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.
Secondary Phase 1: Number of Participants with a Treatment-Related Adverse Event(s) (TRAE[s]) Phase 1: Number of Participants with a TRAE(s) From the time of informed consent, for approximately 24 months (or earlier if the participant discontinues from the study), and through Safety Follow-up (28 days after the last dose)
Secondary Phase 1: Number of Participants with an Abnormal Laboratory or Physical Exam Result(s) Phase 1: Number of Participants with an Abnormal Laboratory or Physical Exam Result(s) From the time of informed consent, for approximately 24 months (or earlier if the participant discontinues from the study), and through Safety Follow-up (28 days after the last dose)
Secondary Phase 1: Overall Response Rate (ORR) based on RECIST 1.1 or RANO, as Appropriate to Tumor Type Phase 1: ORR based on RECIST 1.1 or RANO, as Appropriate to Tumor Type Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed
Secondary Phase 2: ORR (by Investigator) Phase 2: ORR (by Investigator) Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed
Secondary Phase 2: Best Change in Tumor Size from Baseline (by IRC and Investigator) Phase 2: Best Change in Tumor Size from Baseline (by IRC and Investigator) Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed
Secondary Phase 2: Duration of Response (DOR; by IRC and Investigator) Phase 2: DOR (by IRC and Investigator) Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed
Secondary Phase 2: Central Nervous System (CNS) ORR (by IRC) Phase 2: CNS ORR (by IRC) Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed
Secondary Phase 2: CNS DOR (by IRC) Phase 2: CNS DOR (by IRC) Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed
Secondary Phase 2: Time to Any and Best Response (by IRC and Investigator) Phase 2: Time to Any and Best Response (by IRC and Investigator) every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed
Secondary Phase 2: CBR (by IRC and Investigator) Phase 2: CBR (by IRC and Investigator) Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed
Secondary Phase 2: PFS (by IRC and Investigator) Phase 2: PFS (by IRC and Investigator) Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed
Secondary Phase 2: Overall Survival (OS) Phase 2: OS Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed
Secondary Phase 2: Percentage of Participants with any Serious Adverse Event (SAE[s]) Phase 2: Percentage of Participants with any SAE(s) From the time of informed consent, for approximately 24 months (or earlier if the participant discontinues from the study), and through Safety Follow-up (28 days after the last dose)
Secondary Phase 1 and 2: Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve of LOXO-292 (Selpercatinib) Phase 1 and 2: PK: AUC of LOXO-292 (Selpercatinib) Cycle 1 Day 1 through Cycle 5 Day 1 (Cycle = 28 days)
Secondary Phase 1 and 2: PK: Maximum Concentration (Cmax) of LOXO-292 (Selpercatinib) Phase 1 and 2: PK: Cmax of LOXO-292 (Selpercatinib) Cycle 1 Day 1 through Cycle 5 Day 1 (Cycle = 28 days)
See also
  Status Clinical Trial Phase
Terminated NCT03087448 - Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Phase 1
Recruiting NCT05042375 - A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Phase 3
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Terminated NCT05414123 - A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Recruiting NCT05009836 - Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03219970 - Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
Recruiting NCT05949619 - A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors Phase 1/Phase 2
Recruiting NCT04054531 - Study of KN046 With Chemotherapy in First Line Advanced NSCLC Phase 2
Withdrawn NCT03519958 - Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Terminated NCT02580708 - Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer Phase 1/Phase 2
Completed NCT01871805 - A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Terminated NCT04042480 - A Study of SGN-CD228A in Advanced Solid Tumors Phase 1
Recruiting NCT05919641 - LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
Completed NCT03656705 - CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma Phase 1